Dr. Andrew Branagan on A New Flu Vaccine for Patients With Myeloma

January 6, 2016
Andrew Branagan, MD

Branagan said in his study, which gave patients with myeloma a high-dose flu vaccine followed by a booster dose 30 days later, 66% of patients saw total serum protection from the ailment. he said previous efforts to vaccinate patients with myeloma has resulted in a 20% total serum protection.

Andrew Branagan, MD, oncologist, Yale Cancer Center, discusses a recent study addressing the issue of patients with myeloma contracting the flu. Branagan said in his study, which gave patients with myeloma a high-dose flu vaccine followed by a booster dose 30 days later, 66% of patients saw total serum protection from the ailment. he said previous efforts to vaccinate patients with myeloma has resulted in a 20% total serum protection.